Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$115.45 USD
-6.63 (-5.43%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $115.48 +0.03 (0.03%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$115.45 USD
-6.63 (-5.43%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $115.48 +0.03 (0.03%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) reported fourth-quarter 2016 earnings of 50 cents per share (including the impact of stock-based compensation expense), down 11.1% from the year-ago figure.
Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More
by Zacks Equity Research
The fourth-quarter earnings season is drawing to a close with results from 411 S&P 500 members or 82.2% of the index's total membership already out, as of Feb 22, 2017.
Forget Alexion, Buy these 4 Biotech Stocks Instead
by Arpita Dutt
We advise investors to consider biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.
Ligand (LGND) Q4 Earnings: Will the Stock Pull a Surprise?
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report fourth-quarter 2016 results on Feb 23, after the market closes.
The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
Ligand (LGND) Signs Licensing Deals with Ono and Novartis
by Zacks Equity Research
Ligand Pharmaceuticals announced that it has entered into a worldwide license agreement with Ono Pharmaceutical under which Ono will use its OmniAb platform for the discovery of fully human mono- and bispecific antibodies.